Landos Biopharma, Inc.

Landos Biopharma, Inc. (www.landosbiopharma.com) is a clinical-stage biotechnology company. The Company is engaged in focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. The Company through its artificial intelligence (AI)-based precision medicine platform, LANCE platform, identifies therapeutic targets based on predictions of immunometabolic function and create therapeutic candidates to engage those targets in areas of unmet medical need. Its platform discovers small molecule therapeutics for patients with autoimmune diseases that targets mechanisms of action, including LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. It identifies novel immunometabolic targets and product candidates across indications, such as ulcerative colitis (UC), Crohn’s disease (CD), eosinophilic esophagitis (EoE), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its Omilancor is an oral, gut restricted LANCL2 agonist in development for the treatment of UC, CD and EoE.

• Landos Biopharma, Inc.